Cellular and synaptic mechanisms for Parkinson's disease-related chronic pain. (March 2021)

• Record Type: Journal Article
• Authors: Lu, Jing-Shan; Chen, Qi-Yu; Chen, Xiang; Li, Xu-Hui; Zhou, Zhaoxiang; Liu, Qin; Lin, Yuwan; Zhou, Miaomiao; Xu, Ping-Yi; Zhuo, Min
• Is Part Of: Molecular pain. Volume 17(2021)
• Publication Date: 2021-03
• Subjects: Parkinson's disease -- pain -- dopamine -- cortex; Pain -- Molecular aspects -- Periodicals; Pain -- Pathophysiology -- Periodicals; Pain -- Physiological aspects -- Periodicals; 616.0472
• DOI: 10.1177/1744806921999025
• Languages: English
• ISSNs: 1744-8069

Abstract

Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's disease. Chronic pain is experienced by the vast majority of patients living with Parkinson's disease. The degeneration of dopaminergic neuron acts as the essential mechanism of Parkinson's disease in the midbrain dopaminergic pathway. The impairment of dopaminergic neurons leads to dysfunctions of the nociceptive system. Key cortical areas, such as the anterior cingulate cortex (ACC) and insular cortex (IC) that receive the dopaminergic projections are involved in pain transmission. Dopamine changes synaptic transmission via several pathway, for example the D2-adenly cyclase (AC)-cyclic AMP (cAMP)-protein kinase A (PKA) pathway and D1-G protein-coupled receptor kinase 2 (GRK2)-fragile X mental retardation protein (FMRP) pathway. The management of Parkinson's disease-related pain implicates maintenance of stable level of dopaminergic drugs and analgesics, however a more selective drug targeting at key molecules in Parkinson's disease-related pain remains to be investigated.